What is Pharmaceutical Counterfeiting? Counterfeit goods are an age-old consequence of economic markets. These consequences are especially troubling when raising concerns about the delivery of prescription medicines that the public…
Category: Pharmaceutical Drugs
US Pharma Company, Gilead Sciences, Expands Access to COVID-19 Treatment- Experts Remain Skeptical of Long-Term Demands
As healthcare systems around the world continue to struggle with managing the rates of transmission and mortality in patients with COVID-19, an announcement made in late April by Dr. Anthony…
Innovating with Yesterday’s Inventions: Repurposing Drugs for New Indications
Pharmaceutical research and development (R&D) has skyrocketed in recent years and is projected to reach even greater levels in the future. The total R&D spending has increased by 33 billion…
in Access to Medicines, Blogs, Commercialization, Development, Innovation, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
676
Broken Promises: Utility Standards and Patent Applications in Canada
The last day of June 2017 saw the Supreme Court of Canada (SCC) quash the controversial Promise Doctrine. The issue at hand in AstraZeneca Canada Inc v Apotex Inc was…
in Access to Medicines, Commercialization, Design, Development, IP, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
914
What Makes It My Molecule: A Look at Professor Ronald Pearlman’s Genome Editing Work
This past November, Professor Ronald E. Pearlman from York University’s Department of Biology gave a talk [1] at Osgoode Hall Law School to discuss the potential of the innovative CRISPR…
Bringing Biologics in from the Cold: Does Canada’s IP Regime Need a Booster?
As ratification stutters for the Comprehensive Economic and Trade Agreement (CETA), the much-maligned free-trade deal between Canada and the European Union, debate continues as to whether the Canadian intellectual property…